Organon & Co.

OGN Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.76 0.00 0.00%
Market cap
$3.6B
P/E
17.4×
Fwd P/E
5.2×
Dividend yield
0.58%
F-score
5/9
Altman Z
1.09
Beneish M
−2.68
Dividend safety
45/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Piotroski F-Score
5 5 4 5 4 — — — —
P/E ratio
9.96 4.45 3.66 7.80 5.71 4.54 4.54 4.54 4.54
Altman Z-Score
1.09 1.27 1.26 1.51 1.52 — — — —
P/S ratio
0.30 0.60 0.60 1.16 1.22 1.35 1.35 1.35 1.35
Altman Z″-Score (non-manufacturers)
1.78 1.81 1.68 1.64 1.41 — — — —
P/FCF ratio
4.48 5.78 8.29 13.09 3.91 3.39 3.39 3.39 3.39
Beneish M-Score
(2.68) (2.62) (2.21) (2.40) (3.56) (2.93) — — —
P/Operating CF
13.20 9.83 9.46 26.71 164.26 6.48 6.48 6.48 6.48
Dividend Safety Score
45 — — — — — — — —
P/B ratio
2.47 8.13 0.00 0.00 0.00 1.79 1.79 1.79 1.79
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
1.60 1.88 1.89 2.48 2.56 1.49 1.49 1.49 1.49
EV/EBITDA
6.92 7.24 7.92 8.61 8.38 3.75 3.75 3.75 3.75
EV/Operating CF
14.19 12.82 14.80 17.88 7.46 3.40 3.40 3.40 3.40
EV/FCF
23.93 18.16 26.10 28.15 8.16 3.76 3.76 3.76 3.76
Quick Ratio
0.80 0.75 0.84 0.87 0.82 0.39 1.34 1.20 —
Current Ratio
1.82 1.60 1.54 1.56 1.45 1.33 2.95 2.40 —
Net Debt/EBITDA
5.62 4.94 5.40 4.61 4.69 0.01 (0.05) (0.02) 0.00
Debt/Assets
67.18% 67.78% 72.65% 81.36% 85.52% 0.31% 1.12% 0.00% 0.00%
Debt/Equity
11.49 18.81 (125.14) (9.99) (6.06) 0.01 0.02 0.00 —
Asset Turnover
0.48 0.51 0.54 0.57 0.61 0.63 1.47 0.00 0.00
Operating CF/Net income
3.74 1.09 0.78 0.94 1.60 1.06 0.94 1.71 1.90
Capex/Depreciation
(0.47) (0.96) (1.07) (1.48) (1.93) (1.76) (0.26) (0.04) 0.00
Interest Coverage
1.63 2.64 2.39 3.72 6.94 174.75 194.53 129.95 261.76
ROE
30.56% 429.85% (212.68%) (76.42%) 67.92% 34.50% 48.09% 32.18% 0.00%
ROA
1.44% 6.87% 8.89% 8.48% 13.00% 20.91% 61.02% 0.00% 0.00%
ROIC
5.84% 9.90% 9.82% 13.41% 16.25% 31.74% 33.80% 0.00% —
Return on Tangible Assets
5.73% 30.88% 36.89% 37.63% 63.25% 115.02% 97.69% 76.35% 0.00%
Average Days of Receivables
78.16 77.41 101.64 87.20 80.02 58.00 69.18 59.92 0.00
Research and Development Expense of Revenue
5.89% 7.32% 8.43% 7.63% 5.38% 3.21% 2.83% 3.73% 3.38%
Selling, General and Administrative Expense of Revenue
27.69% 27.49% 30.23% 27.60% 26.46% 20.76% 18.55% 20.59% 21.76%
Intangible Assets out of Total Assets
0.41 0.47 0.43 0.48 0.49 0.51 0.49 0.00 0.00
Share Based Compensation of Revenue
1.24% 1.64% 1.61% 1.21% 0.94% 0.61% 0.53% 0.57% 0.00%
Graham Net Nets
(4.17) (2.16) (2.03) (1.11) (1.09) (0.23) (0.23) (0.23) (0.23)
Graham Number
6.85 11.76 0.00 0.00 0.00 64.41 0.00 0.00 0.00
Earnings Yield
10.04% 22.45% 27.33% 12.83% 17.50% 22.04% 22.04% 22.04% 22.04%
Free Cash Flow Yield
22.30% 17.29% 12.07% 7.64% 25.58% 29.46% 29.46% 29.46% 29.46%
Revenue per Share
23.95 24.91 24.54 24.30 24.86 25.77 30.68 38.64 41.50
Operating CF per Share
2.70 3.65 3.13 3.38 8.52 9.01 11.91 14.57 13.51
Capex per Share
(1.10) (1.07) (0.99) (1.23) (1.49) (0.99) (0.35) (0.27) 0.00
Free Cash Flow per Share
1.60 2.58 2.14 2.15 7.03 8.02 11.57 14.30 13.51
Cash per Share
2.21 2.63 2.72 2.78 2.91 0.05 1.26 0.96 0.00
Shareholders Equity per Share
2.90 1.84 (0.27) (3.51) (5.95) 21.64 27.75 0.00 0.00
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
2.90 1.84 (0.27) (3.51) (5.95) 21.64 27.75 0.00 0.00
Free Cash Flow
415.00 663.00 547.00 545.00 1,783.00 2,034.00 2,932.00 3,618.00 3,419.00
Working Capital
1,962.00 1,630.00 1,590.00 1,419.00 1,163.00 894.00 2,614.00 2,169.00 —
Capital Expenditures
(285.00) (276.00) (252.00) (313.00) (377.00) (250.00) (88.00) (69.00) (86.00)
Net Current Asset Value
(7,763.00) (8,281.00) (7,620.00) (7,916.00) (8,429.00) (1,056.00) 442.00 3,714.00 —
EV/EBIT
12.05 8.76 9.40 9.77 9.00 4.01 4.01 4.01 4.01
Capex to Sales
0.05 0.04 0.04 0.05 0.06 0.04 0.01 0.01 0.00
Price to Operating Income
2.26 2.79 2.99 4.54 4.31 3.63 3.63 3.63 3.63
Other line items
Depreciation/Fixed assets
0.47 0.25 0.20 0.21 0.20 0.14 0.49 2.57 0.00
Cash ROIC
4.16% 6.61% 5.83% 6.24% 21.32% 36.79% 39.24% 920.61% 0.00%
Accounts Receivable Turnover
4.62 4.13 3.89 4.32 5.21 5.20 5.05 6.35 0.00
Accounts Payable Turnover
2.76 2.18 2.06 1.83 2.90 8.20 8.31 17.16 0.00
Inventory Turnover
2.13 2.04 2.17 2.39 2.61 2.14 2.20 4.55 0.00
Average Days of Payables
119.70 156.56 190.70 180.11 211.77 44.61 41.41 22.48 0.00
Days of Inventory on Hand
176.78 179.38 190.84 159.59 140.21 157.27 171.91 77.31 0.00
Average Receivables
1,344.50 1,551.00 1,609.50 1,428.50 1,210.00 1,256.00 1,539.50 1,539.50 —
Average Payables
1,052.50 1,233.50 1,223.00 1,257.00 820.50 258.50 273.50 273.50 —
Average Inventory
1,363.50 1,318.00 1,159.00 959.00 914.00 992.00 1,032.50 1,032.50 —
Average Assets
12,984.00 12,579.50 11,506.50 10,818.00 10,395.00 10,328.50 5,274.00 0.00 —
Average Common Equity
612.00 201.00 (481.00) (1,200.00) 1,989.00 6,260.50 6,691.50 6,691.50 —

Fold the line items

Columns are period end dates